- In April 2023, BIOTRONIK announced the commercial launch of its Orsiro Mission Drug-eluting stent system in Canada, following its approval by Health Canada. This advanced system aims to enhance coronary luminal diameter in patients suffering from diabetes and other diseases. BIOTRONIK is replacing the original Orsiro system with this latest generation, offering improved performance and therapeutic options for patients with coronary artery disease
- In March 2022, S3V Vascular Technologies, a prominent medical device firm, revealed plans to invest INR 250 crore to build a state-of-the-art stent manufacturing facility at Telangana Medical Devices Park, near Hyderabad. The facility aims to enhance production capabilities for stents, which are crucial for cardiovascular procedures. This move is part of the company's strategy to meet the growing demand for high-quality, locally manufactured medical devices in India
- In February 2022, The Orsiro Coronary Drug-Eluting Stent (DES) by BIOTRONIK, with its Ultrathin Strut design, set a new clinical benchmark for cardiovascular treatments. The final 5-year data from the BIOFLOW-V trial reinforced the stent's superior safety profile, confirming Orsiro's status as a gold standard in DES technology. This study further supports the use of Orsiro as a reliable, long-term solution for coronary artery disease
- In March 2021, Meril Life Sciences launched its indigenously developed MeRes100, a bioresorbable scaffold stent. The MeRes100 is a thin-struct bioresorbable stent designed as an alternative to traditional metallic stents. This innovative product offers a promising treatment option by gradually dissolving within the body, reducing long-term complications and the need for further interventions, while still providing adequate support during the healing process for patients with coronary artery disease
- In October 2021, Boston Scientific Corporation unveiled positive results for its Eluvia Drug-Eluting Vascular Stent System at the Vascular InterVentional Advances conference in Las Vegas. The stent system demonstrated impressive clinical outcomes, with higher sustained clinical improvement and superior primary patency rates. This late-breaking trial presentation highlighted the effectiveness of Eluvia in providing long-term vascular support, making it a leading option for treating peripheral artery disease with promising patient outcomes
